Avid Bioservices Inc (CDMO): July 15, 2014 9:56amET “Roth Capital af...

Send PM Follow Ignore

Followers	85
Posts	12714
Boards Moderated	0
Alias Born	10/12/2010

biopharm

Re: cjgaddy post# 183161

Tuesday, 07/15/2014 2:53:33 PM

Tuesday, July 15, 2014 2:53:33 PM

July 15, 2014 9:56amET
“Roth Capital affirms its Buy rating and $5 price target on Peregrine Pharmaceuticals (Nasdaq: PPHM) following Q2 results issued after...” (prem. membership only)
www.streetinsider.com/stock_lookup.php?q=PPHM

Thanks CJ.... unless I am missing a prior upgrade, it looks like ROTH upgraded from $2.70 from back in Jan 2013

All heading in the right direction.

---------

Jan 7, 2013

Roth Capital upgraded Peregrine Pharmaceuticals (NASDAQ: PPHM) from Neutral to Buy with a price target of $2.70 (from $1.25).

For an analyst ratings summary and ratings history on Peregrine Pharmaceuticals click here. For more ratings news on Peregrine Pharmaceuticals click here.

Shares of Peregrine Pharmaceuticals closed at $1.35 yesterday.

Rating Summary:
3 Buy, 0 Hold, 0 Sell

http://www.streetinsider.com/Analyst+PT+Change/Roth+Capital+Upgrades+Peregrine+Pharmaceuticals+%28PPHM%29+to+Buy/7989687.html

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!